Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Marston

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Circulation|August 13, 2019
A Shocking DeficiencyErin H Penn, Benjamin A Olenchock, Nicholas A Marston
The New England Journal of Medicine|April 29, 2026
Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. ReplyNicholas A Marston, Brian A Bergmark, Marc S Sabatine
Circulation|October 26, 2020
Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism"Nicholas A Marston, Christian T Ruff, Marc S Sabatine
The New England Journal of Medicine|December 30, 2025
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. ReplyBrian A Bergmark, Nicholas A Marston, Marc S Sabatine
Heart, Lung & Circulation|December 6, 2025
Letter to the Editor: "No Time to Waste - Upfront Combination Lipid Lowering Therapy for Post-Acute Coronary Syndromes," Regarding the: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025 by Brieger et al., Heart Lung Circ. 2025;34:309-397Ian R Hamilton-Craig, Peter J Psaltis, Nicholas A Marston, et al.
Circulation|August 28, 2021
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dLNicholas A Marston, Robert P Giugliano, Jeong-Gun Park, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Circulation|September 19, 2019
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled TrialsNicholas A Marston, Robert P Giugliano, KyungAh Im, et al.
Journal of the American College of Cardiology|January 17, 2024
Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing LipoproteinsNicholas A Marston, Giorgio E M Melloni, Sabina A Murphy, et al.
Cardiovascular Ultrasound|August 12, 2014
Assessment of left atrial volume before and after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertensionNicholas A Marston, William R Auger, Michael M Madani, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Circulation|August 13, 2019
A Shocking DeficiencyErin H Penn, Benjamin A Olenchock, Nicholas A Marston
The New England Journal of Medicine|April 29, 2026
Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. ReplyNicholas A Marston, Brian A Bergmark, Marc S Sabatine
Circulation|October 26, 2020
Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism"Nicholas A Marston, Christian T Ruff, Marc S Sabatine
The New England Journal of Medicine|December 30, 2025
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. ReplyBrian A Bergmark, Nicholas A Marston, Marc S Sabatine
Heart, Lung & Circulation|December 6, 2025
Letter to the Editor: "No Time to Waste - Upfront Combination Lipid Lowering Therapy for Post-Acute Coronary Syndromes," Regarding the: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025 by Brieger et al., Heart Lung Circ. 2025;34:309-397Ian R Hamilton-Craig, Peter J Psaltis, Nicholas A Marston, et al.
Circulation|August 28, 2021
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dLNicholas A Marston, Robert P Giugliano, Jeong-Gun Park, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Circulation|September 19, 2019
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled TrialsNicholas A Marston, Robert P Giugliano, KyungAh Im, et al.
Journal of the American College of Cardiology|January 17, 2024
Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing LipoproteinsNicholas A Marston, Giorgio E M Melloni, Sabina A Murphy, et al.
Cardiovascular Ultrasound|August 12, 2014
Assessment of left atrial volume before and after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertensionNicholas A Marston, William R Auger, Michael M Madani, et al.
Pageof 9